Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

EP: 1.Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

EP: 2.Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

Now Viewing

EP: 3.Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

EP: 4.The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

Video content above is prompted by the following:

Overall Survival Data from MARIPOSA Trial

Key Themes:

• Significant Survival Improvement: Analysis of the MARIPOSA trial showing amivantamab plus lazertinib leads to improved progression-free survival and overall survival
• Statistical Impact: Overall survival hazard ratio of 0.75 with projected median overall survival exceeding 1 year
• Comparison Considerations: Discussion of MARIPOSA vs FLAURA2 trial designs and outcomes

Notable Insights:

• Dr Dietrich: Called the 12-plus-months overall survival improvement “very refreshing” and noted the “relatively flat trajectory as we move out further on the curve,” indicating durable benefit. He stated, “Breaking through 4 years of overall survival is one thing and...5-year landmark improvements...is also very, very significant.”
• Dr Piotrowska: Emphasized caution when comparing trials, noting that MARIPOSA had “no crossover allowed” while FLAURA2 patients could access chemotherapy in later lines of treatment, making direct comparison of survival outcomes challenging.